Single dose pharmacokinetic study of HP-3060
Phase 2
Completed
- Conditions
- Allergic rhinitis
- Registration Number
- JPRN-jRCT2080223788
- Lead Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 24
Inclusion Criteria
Patients who a diagnosis of allergic rhinitis and symptoms of this condition.
Exclusion Criteria
- Patients who have a history of hypersensitivity to any medicines.
- Patients who may be affected by blood sampling in the study following blood collection or bleeding within 4 weeks prior to study drug administration.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of HP-3060 in modulating IgE pathways for allergic rhinitis treatment?
How does HP-3060 compare to standard-of-care antihistamines in pediatric allergic rhinitis efficacy and safety profiles?
What biomarkers are associated with HP-3060 pharmacokinetic variability in children with allergic rhinitis?
What adverse events were observed in JPRN-jRCT2080223788 and how were they managed in pediatric patients?
Are there combination therapies involving HP-3060 that enhance therapeutic outcomes in allergic rhinitis compared to monotherapy?